Hecker Matthias, Walmrath Hans-Dieter, Seeger Werner, Mayer Konstantin
University of Gieβen Lung Center (UGLC), Gieβen, Germany.
Transfus Med Hemother. 2008;35(2):80-88. doi: 10.1159/000117582. Epub 2008 Mar 10.
Acute respiratory distress syndrome (ARDS) is a common clinical disorder caused by a variety of direct and indirect injuries to the lung, characterized by alveolar epithelial and endothelial injury resulting in damage to the pulmonary alveolar-capillary barrier. The cardinal clinical feature of ARDS, refractory arterial hypoxemia, is the result of protein-rich alveolar edema with impaired surfactant function, due to vascular leakage and vascular dysfunction with consequently impaired matching of ventilation to perfusion. Since its first description in 1967, considerable knowledge concerning the pathogenesis of ARDS has been obtained, however, a plethora of questions remain. Better understanding of the pathophysiology of ARDS has lead to the development of novel therapies, pharmacological strategies, and advances in mechanical ventilation. However, lung-protective ventilation is the only confirmed option in ARDS management improving survival, and few other therapies have translated into improved oxygenation or reduced ventilation time. But despite improvement in our understanding of the therapy and supportive care for patients with ARDS, mortality remains high. It is the purpose of this article to provide an overview of the definition, clinical features, and pathogenesis of ARDS, and to present and discuss therapeutic options currently available in order to effectively treat this severe disorder.
急性呼吸窘迫综合征(ARDS)是一种常见的临床病症,由多种对肺的直接和间接损伤引起,其特征是肺泡上皮和内皮损伤导致肺泡-毛细血管屏障受损。ARDS的主要临床特征——难治性动脉低氧血症,是由于富含蛋白质的肺泡水肿以及表面活性物质功能受损所致,这是血管渗漏和血管功能障碍以及由此导致的通气与灌注匹配受损的结果。自1967年首次描述以来,关于ARDS发病机制已获得了相当多的知识,然而,仍存在大量问题。对ARDS病理生理学的更好理解已促成了新疗法、药理学策略以及机械通气方面的进展。然而,肺保护性通气是ARDS管理中唯一被证实可提高生存率的选择,几乎没有其他疗法能转化为改善氧合或缩短通气时间。尽管我们对ARDS患者的治疗和支持性护理的理解有所改善,但死亡率仍然很高。本文旨在概述ARDS的定义、临床特征和发病机制,并介绍和讨论目前可用的治疗选择,以便有效治疗这种严重病症。